Light sheet fluorescence microscopy for monitoring drug delivery: Unlocking the developmental phases of embryos.

Light sheet fluorescence microscopy (LSFM) has emerged as a transformative imaging technique in the study of drug delivery and embryonic development, offering high-resolution, real-time visualization with minimal phototoxicity. This review examines the application of LSFM in tracking drug pharmacokinetics, tissue-specific targeting, and drug efficacy during critical phases of embryonic development. Recent advancements in fluorescent labeling and machine learning integration have enabled more precise monitoring of drug release, distribution, and interaction with developing tissues.

Overexpression of an NF-YB gene family member, EaNF-YB2, enhances drought tolerance in sugarcane (Saccharum Spp. Hybrid).

Background: Drought is one of main critical factors that limits sugarcane productivity and juice quality in tropical regions. The unprecedented changes in climate such as monsoon failure, increase in temperature and other factors warrant the need for development of stress tolerant cultivars to sustain sugar production. Plant Nuclear factor (NF-Y) is one of the major classes of transcription factors that have a major role in plant development and abiotic stress response.

Interfacial charge transfer on hierarchical synergistic shell wall of MXene/MoS on CdS nanospheres: heterostructure integrity for visible light responsive photocatalytic H evolution.

Energy scarcity and environmental pollution have prompted research in hydrogen generation from solar to develop clean energy through highly efficient, effective, and long-lasting photocatalytic systems. Designing a catalyst with robust stability and an effective carrier separation rate was achieved through heterostructure assembly, but certain functionalities must be explored. In this paper we designed a ternary heterostructure assembly of CdS nanospheres wrapped with hierarchical shell walls of layered MXene-tagged MoS nanoflakes, forming intimate interfaces through an in-situ growth process.

Expediting treatments in the 21st century: orphan drugs and accelerated approvals.

Background: In response to activated patient communities' catalyzation, two significant efforts by the FDA to expedite treatments have now been in place for multiple decades. In 1983, the United States Congress passed the Orphan Drug Act to provide financial incentives for development of drugs for rare diseases. In 1992, partly in response to the HIV epidemic, the FDA implemented Accelerated Approval (AA) to expedite access to promising new therapies to treat serious conditions with unmet medical need based on surrogate marker efficacy while additional clinical data is confirmed.